Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Grossmann

Showing results (51-60 of 76) with videos related to

Pageof 8
Sort By:
Cancer Medicine|January 27, 2015
Clinical outcomes associated with evolving treatment modalities and radiation techniques for base-of-tongue carcinoma: thirty years of institutional experienceLeechuan Andy Chen, Christopher J Anker, Jason P Hunt, et al.
Journal for Immunotherapy of Cancer|January 27, 2021
Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanomaRebecca Pokorny, Jordan P McPherson, Benjamin Haaland, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 8, 2013
Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanomaChristopher J Anker, Antoni Ribas, Allie H Grossmann, et al.
Cancers|May 13, 2023
Granulomatous and Sarcoid-like Immune-Related Adverse Events following CTLA4 and PD1 Blockade Adjuvant Therapy of Melanoma: A Combined Analysis of ECOG-ACRIN E1609 and SWOG S1404 Phase III Trials and a Literature ReviewIslam Eljilany, Arish Noor, Mahati Paravathaneni, et al.
Journal of Pharmaceutical Sciences|April 24, 2013
Effects of particle size, food, and capsule shell composition on the oral bioavailability of dabrafenib, a BRAF inhibitor, in patients with BRAF mutation-positive tumorsDaniele Ouellet, Kenneth F Grossmann, Giselle Limentani, et al.
Journal of Neuro-Oncology|August 31, 2012
Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiformeKenneth F Grossmann, Howard Colman, Wallace A Akerley, et al.
Journal of the American Academy of Dermatology|December 31, 2013
Patterns of failure and predictors of outcome in cutaneous malignant melanoma of the scalpBreanne E Terakedis, Christopher J Anker, Sancy A Leachman, et al.
Science Signaling|March 7, 2013
The small GTPase ARF6 stimulates β-catenin transcriptional activity during WNT5A-mediated melanoma invasion and metastasisAllie H Grossmann, Jae Hyuk Yoo, James Clancy, et al.
British Journal of Clinical Pharmacology|December 16, 2017
Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600-mutant tumoursNoelia Nebot, Hendrik-Tobias Arkenau, Jeffrey R Infante, et al.
Melanoma Research|June 21, 2019
Recurrence risk of early-stage melanoma of the external ear: an investigation of surgical approach and sentinel lymph node statusAmanda Truong, John R Hyngstrom, Robert H I Andtbacka, et al.
Pageof 8

Showing results (51-60 of 76) with videos related to

Sort By:
Pageof 8
Cancer Medicine|January 27, 2015
Clinical outcomes associated with evolving treatment modalities and radiation techniques for base-of-tongue carcinoma: thirty years of institutional experienceLeechuan Andy Chen, Christopher J Anker, Jason P Hunt, et al.
Journal for Immunotherapy of Cancer|January 27, 2021
Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanomaRebecca Pokorny, Jordan P McPherson, Benjamin Haaland, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 8, 2013
Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanomaChristopher J Anker, Antoni Ribas, Allie H Grossmann, et al.
Cancers|May 13, 2023
Granulomatous and Sarcoid-like Immune-Related Adverse Events following CTLA4 and PD1 Blockade Adjuvant Therapy of Melanoma: A Combined Analysis of ECOG-ACRIN E1609 and SWOG S1404 Phase III Trials and a Literature ReviewIslam Eljilany, Arish Noor, Mahati Paravathaneni, et al.
Journal of Pharmaceutical Sciences|April 24, 2013
Effects of particle size, food, and capsule shell composition on the oral bioavailability of dabrafenib, a BRAF inhibitor, in patients with BRAF mutation-positive tumorsDaniele Ouellet, Kenneth F Grossmann, Giselle Limentani, et al.
Journal of Neuro-Oncology|August 31, 2012
Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiformeKenneth F Grossmann, Howard Colman, Wallace A Akerley, et al.
Journal of the American Academy of Dermatology|December 31, 2013
Patterns of failure and predictors of outcome in cutaneous malignant melanoma of the scalpBreanne E Terakedis, Christopher J Anker, Sancy A Leachman, et al.
Science Signaling|March 7, 2013
The small GTPase ARF6 stimulates β-catenin transcriptional activity during WNT5A-mediated melanoma invasion and metastasisAllie H Grossmann, Jae Hyuk Yoo, James Clancy, et al.
British Journal of Clinical Pharmacology|December 16, 2017
Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600-mutant tumoursNoelia Nebot, Hendrik-Tobias Arkenau, Jeffrey R Infante, et al.
Melanoma Research|June 21, 2019
Recurrence risk of early-stage melanoma of the external ear: an investigation of surgical approach and sentinel lymph node statusAmanda Truong, John R Hyngstrom, Robert H I Andtbacka, et al.
Pageof 8